You are here:HomeLive TVVideosOral Insulin Can Be A Blockbuster Opportunity: Kiran Mazumdar-shaw

Oral insulin can be a blockbuster opportunity: Kiran Mazumdar-Shaw

loading..

Biocon has just brought in Bristol Meyers as a partner for its oral insulin drug. Bristol will fund the clinical trials and, if successful, the rest of the deal will be triggered. Kiran Mazumdar-Shaw, CMD, Biocon, is hopeful of the same and thinks this is a blockbuster opportunity.

MORE FROM NDTV

FROM THE WEB

MORE FROM THE WEB
MORE FROM NDTV

Social Sharing

Advertisement

Advertisement

Portfolio
 

More From NDTV

More From the WEB

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2014. All rights reserved.